PIK3CA and cancer: Here, we demonstrated that SHR8443, a novel orally available inhibitor of PI3K/mTOR signaling, exhibited broad antitumor activity against human cancer cell lines independent of their genetic backgrounds both in vitro and in vivo, notably overcoming resistance to targeted anticancer therapies.